

# Arun Sahai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9421319/publications.pdf>

Version: 2024-02-01

122  
papers

2,583  
citations

236925

25  
h-index

206112

48  
g-index

122  
all docs

122  
docs citations

122  
times ranked

2461  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial. <i>Journal of Urology</i> , 2007, 177, 2231-2236.	0.4	285
2	Nonantibiotic prevention and management of recurrent urinary tract infection. <i>Nature Reviews Urology</i> , 2018, 15, 750-776.	3.8	155
3	Recent advances in the diagnosis and treatment of bladder cancer. <i>BMC Medicine</i> , 2013, 11, 13.	5.5	142
4	Attitudes of medical and dental students to dissection. <i>Clinical Anatomy</i> , 2003, 16, 165-172.	2.7	137
5	Repeated Botulinum Toxin Type A Injections for Refractory Overactive Bladder: Medium-Term Outcomes, Safety Profile, and Discontinuation Rates. <i>European Urology</i> , 2012, 61, 834-839.	1.9	120
6	Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. <i>BJU International</i> , 2014, 113, 789-794.	2.5	95
7	Percutaneous versus Open Tendo Achillis Repair. <i>Foot and Ankle International</i> , 2004, 25, 215-218.	2.3	92
8	Guideline of guidelines: bladder pain syndrome. <i>BJU International</i> , 2018, 122, 729-743.	2.5	79
9	Improvement in quality of life after botulinum toxin A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. <i>BJU International</i> , 2009, 103, 1509-1515.	2.5	74
10	Repeated Injections of Botulinum Toxin-A for Idiopathic Detrusor Overactivity. <i>Urology</i> , 2010, 75, 552-558.	1.0	69
11	Nerve growth factor (<sc>NGF</sc>): a potential urinary biomarker for overactive bladder syndrome (<sc>OAB</sc>)? <i>BJU International</i> , 2013, 111, 372-380.	2.5	68
12	Botulinum toxin for the treatment of lower urinary tract symptoms: A review. <i>Neurourology and Urodynamics</i> , 2005, 24, 2-12.	1.5	59
13	Eosinophilic cystitis and its management. <i>International Journal of Clinical Practice</i> , 2005, 59, 356-360.	1.7	56
14	Simulation-Based Ureteroscopy Training: A Systematic Review. <i>Journal of Surgical Education</i> , 2015, 72, 135-143.	2.5	55
15	The Relationship Between Technical And Nontechnical Skills Within A Simulation-Based Ureteroscopy Training Environment. <i>Journal of Surgical Education</i> , 2015, 72, 1039-1044.	2.5	54
16	Simulation-based ureteroscopy skills training curriculum with integration of technical and non-technical skills: a randomised controlled trial. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 2728-2735.	2.4	54
17	Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin A: is incomplete bladder emptying predictable?. <i>BJU International</i> , 2009, 103, 630-634.	2.5	46
18	Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICIERS 2015). <i>Neurourology and Urodynamics</i> , 2017, 36, 882-893.	1.5	44

#	ARTICLE	IF	CITATIONS
19	Urodynamic Assessment of Poor Responders After Botulinum Toxin-A Treatment for Overactive Bladder. <i>Urology</i> , 2008, 71, 455-459.	1.0	42
20	Getting out of a tight spot: an overview of ureteroenteric anastomotic strictures. <i>Nature Reviews Urology</i> , 2016, 13, 447-455.	3.8	36
21	The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. <i>International Journal of Clinical Practice</i> , 2011, 65, 698-704.	1.7	32
22	Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management. <i>Current Urology Reports</i> , 2011, 12, 404-412.	2.2	32
23	The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics database. <i>BJU International</i> , 2014, 114, 268-277.	2.5	32
24	Persistence with mirabegron therapy for overactive bladder: A real life experience. <i>Neurourology and Urodynamics</i> , 2017, 36, 404-408.	1.5	30
25	What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. <i>Neurourology and Urodynamics</i> , 2014, 33, 602-605.	1.5	27
26	The psychology of LUTS: ICI-RS 2011. <i>Neurourology and Urodynamics</i> , 2012, 31, 340-343.	1.5	26
27	Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. <i>Nature Reviews Urology</i> , 2010, 7, 661-667.	3.8	24
28	Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. <i>Therapeutic Advances in Urology</i> , 2017, 9, 3-10.	2.0	24
29	Video consent: a pilot study of informed consent in laparoscopic urology and its impact on patient satisfaction. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2006, 10, 21-5.	1.1	24
30	Techniques for the intradetrusor administration of botulinum toxin. <i>BJU International</i> , 2006, 97, 675-678.	2.5	22
31	Feasibility of using a novel non-invasive ambulatory tibial nerve stimulation device for the home-based treatment of overactive bladder symptoms. <i>Translational Andrology and Urology</i> , 2018, 7, 912-919.	1.4	22
32	What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S108-S116.	1.5	22
33	&lt;p&gt;Clinical Management of Bladder Pain Syndrome/Interstitial Cystitis: A Review on Current Recommendations and Emerging Treatment Options&lt;/p&gt;. <i>Research and Reports in Urology</i> , 2020, Volume 12, 331-343.	1.0	22
34	Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity. <i>Urology</i> , 2019, 123, 242-246.	1.0	21
35	Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder. <i>BJU International</i> , 2015, 116, 443-449.	2.5	20
36	Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 293-298.	1.5	20

#	ARTICLE	IF	CITATIONS
37	Is Percutaneous Nephrolithotomy in Solitary Kidneys Safe?. <i>Urology</i> , 2013, 82, 1013-1016.	1.0	18
38	Use of Duloxetine for Postprostatectomy Stress Urinary Incontinence: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 618-628.	3.1	18
39	Laparoscopic Management of Cryptorchidism in Adults. <i>European Urology</i> , 2005, 48, 453-457.	1.9	17
40	Evolution of transdermal oxybutynin in the treatment of overactive bladder. <i>International Journal of Clinical Practice</i> , 2007, 62, 167-170.	1.7	17
41	Validation of the bladder control self-assessment questionnaire (B&SAQ) in men. <i>BJU International</i> , 2014, 113, 783-788.	2.5	17
42	Laparoscopic Retroperitoneal Nephrectomy for Giant Hydronephrosis: When Simple Nephrectomy Isn't Simple. <i>Journal of Endourology</i> , 2007, 21, 437-440.	2.1	14
43	The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 529-538.	1.8	13
44	Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going. <i>Nature Reviews Urology</i> , 2007, 4, 379-386.	1.4	13
45	Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder. <i>Urology</i> , 2020, 135, 32-37.	1.0	13
46	Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies. <i>International Journal of Clinical Practice</i> , 2015, 69, 1184-1208.	1.7	12
47	The role of male slings in post prostatectomy incontinence: ICI&RS 2015. <i>Neurourology and Urodynamics</i> , 2017, 36, 927-934.	1.5	12
48	How can we prevent postprostatectomy urinary incontinence by patient selection, and by preoperative, peroperative, and postoperative measures? International Consultation on Incontinence&Research Society 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S119-S126.	1.5	12
49	Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 1448-1467.	3.1	12
50	Overactive bladder and sexual function: a nightmare couple. <i>BJU International</i> , 2012, 110, 921-924.	2.5	11
51	Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder. <i>Current Medical Research and Opinion</i> , 2014, 30, 1557-1564.	1.9	11
52	A national UK audit of suprapubic catheter insertion practice and rate of bowel injury with comparison to a systematic review and meta-analysis of available research. <i>Neurourology and Urodynamics</i> , 2019, 38, 2194-2199.	1.5	11
53	A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. <i>BJU International</i> , 2006, 97, 413-414.	2.5	10
54	British Association of Urological Surgeons (BAUS) consensus document: management of bladder and ureteric injury. <i>BJU International</i> , 2021, 128, 539-547.	2.5	10

#	ARTICLE	IF	CITATIONS
55	Role of laparoscopic nephrectomy for refractory hypertension in poorly functioning kidneys. Annals of the Royal College of Surgeons of England, 2011, 93, 25-26.	0.6	8
56	Botulinum Toxin—What Urologic Uses Does the Data Support?. Current Urology Reports, 2013, 14, 227-234.	2.2	8
57	The use of botulinum toxin for the treatment of urologic pain. Current Opinion in Urology, 2013, 23, 570-578.	1.8	8
58	How can we improve the diagnosis and management of bladder pain syndrome? Part 2: ICI—RS 2018. Neurourology and Urodynamics, 2019, 38, S71-S81.	1.5	8
59	PDE-5 Inhibitors for BPH-Associated LUTS. Current Drug Targets, 2015, 16, 1180-1186.	2.1	8
60	The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 509-527.	1.8	7
61	Laparoscopic pyeloplasty and pyelopyelostomy for ureteropelvic junction obstruction in a duplicated collecting system. Urology, 2006, 67, 199.e9-199.e11.	1.0	7
62	Laparoscopic upper urinary tract surgery for benign and malignant conditions. Does aetiology have an effect on health-related quality of life?*. International Journal of Clinical Practice, 2007, 61, 2026-2029.	1.7	7
63	Endovascular management of grade V blunt renal trauma with associated splenic injury. Nature Reviews Urology, 2009, 6, 335-337.	3.8	7
64	British Association of Urological Surgeons (BAUS) consensus document: Management of female voiding dysfunction. BJU International, 2022, 129, 151-159.	2.5	7
65	Applications of electromotive drug administration in urology. Urology Annals, 2020, 12, 301.	0.6	7
66	Botulinum toxin-A for the treatment of overactive bladder: UK contributions. Journal of Clinical Urology, 2013, 6, 77-83.	0.1	6
67	Urethral Sphincter Injection of Botulinum Toxin A: Review of Its Application and Outcomes. LUTS: Lower Urinary Tract Symptoms, 2018, 10, 109-115.	1.3	6
68	How can we better manage drug-resistant OAB/DO? ICI—RS 2018. Neurourology and Urodynamics, 2019, 38, S46-S55.	1.5	6
69	Is pre-operative urodynamic bladder function the true predictor of outcome of male sling for post prostatectomy incontinence?. World Journal of Urology, 2021, 39, 1227-1232.	2.2	6
70	Botulinum toxin: A new dimension in the treatment of lower urinary tract dysfunction. Urology, 2005, 65, 211.	1.0	5
71	Current State of the Art in Non-Invasive Urodynamics. Current Bladder Dysfunction Reports, 2013, 8, 83-91.	0.5	5
72	Periurethral Non-animal Stabilized Hyaluronic Acid/Dextranomer Injections: Efficacy and Formation of Granuloma/Sterile Abscess. Urology, 2009, 74, 486-488.	1.0	4

#	ARTICLE	IF	CITATIONS
73	How can we improve the diagnosis and management of bladder pain syndrome? Part 1: ICIâ€RS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S66-S70.	1.5	4
74	Shifting the treatment paradigm in idiopathic overactive bladder. <i>International Journal of Clinical Practice</i> , 2021, 75, e13847.	1.7	4
75	Preâ€prostectomy membranous urethral length as a predictive factor of post prostatectomy incontinence requiring surgical intervention with an artificial urinary sphincter or a male sling. <i>Neurourology and Urodynamics</i> , 2022, 41, 973-979.	1.5	4
76	Laparoscopic ureteroneocystostomy for benign lower ureteric stricture: case study and literature review. <i>International Journal of Clinical Practice</i> , 2005, 59, 115-117.	1.7	3
77	Testicular pain as a presentation of Cowden syndrome. <i>Annals of the Royal College of Surgeons of England</i> , 2011, 93, e51-e52.	0.6	3
78	SINGLE CENTRE RANDOMISED PILOT STUDY OF TWO REGIMENS (30 MINS DAILY OR 30 MINS WEEKLY FOR 12) Tj ETQq0 0 0 rgBT /Over SCLEROSIS-RELATED OVERACTIVE BLADDER SYMPTOMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.20-e4.	1.9	3
79	Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. <i>Urology</i> , 2021, 149, 1-10.	1.0	3
80	Bladder pain syndrome/interstitial cystitis in contemporary UK practice: Outcomes of phenotypeâ€directed management. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 123-128.	1.3	3
81	The role of dry-lab and cadaveric simulation for cystoscopy and intravesical Botulinum toxin injections. <i>Translational Andrology and Urology</i> , 2019, 8, 673-677.	1.4	3
82	Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation?. <i>Neurourology and Urodynamics</i> , 2022, 41, 1172-1176.	1.5	3
83	INFORMED CONSENT: ARE WE DELUDING OURSELVES? A RANDOMIZED CONTROLLED STUDY. <i>BJU International</i> , 2007, 99, 943-943.	2.5	2
84	EFFICACY AND COMPLICATIONS OF INTRADETRUSOR INJECTION WITH BOTULINUM TOXIN A IN PATIENTS WITH REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY. <i>BJU International</i> , 2008, 101, 515-516.	2.5	2
85	Bipolar Transurethral Resection of Prostate: Current Status in the Management of Bladder Outflow Obstruction. <i>British Journal of Medical and Surgical Urology</i> , 2012, 5, 105-110.	0.2	2
86	Lower Urinary Tract Dysfunction in Multiple Sclerosis. <i>Current Bladder Dysfunction Reports</i> , 2012, 7, 97-104.	0.5	2
87	Re: Marcus J. Drake, Amanda L. Lewis, Grace J. Young, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. <i>Eur Urol</i> 2020;78:701â€10. <i>European Urology</i> , 2020, 78, e232-e233.	1.9	2
88	Clear cell carcinoma in a urethral diverticulum. <i>Urology Case Reports</i> , 2020, 32, 101164.	0.3	2
89	Total Pelvic Exenteration for Locally Advanced and Recurrent Rectal Cancer: Urological Outcomes and Adverse Events. <i>European Urology Focus</i> , 2020, 7, 638-643.	3.1	2
90	Is botulinum toxin type A a safe and effective treatment for neurogenic urinary incontinence?. <i>Nature Reviews Urology</i> , 2005, 2, 530-531.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Is botulinum A toxin an effective treatment for idiopathic detrusor overactivity and sensory urgency?. Nature Reviews Urology, 2007, 4, 136-137.	1.4	1
92	Laparoscopic Nephrectomy in a Patient with Ankylosing Spondylitis: Surgical and Anesthetic Challenges. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2007, 17, 223-225.	1.0	1
93	BOTULINUM TOXIN A IN THE OVERACTIVE BLADDER: CURRENT STATUS AND FUTURE DIRECTIONS. BJU International, 2007, 99, 1549-1550.	2.5	1
94	Should we inject the trigone during botulinum toxin injection?. Nature Reviews Urology, 2012, 9, 129-130.	3.8	1
95	Overactive bladder in men: initial assessment. Trends in Urology & Men's Health, 2012, 3, 7-12.	0.4	1
96	Efficacy of flexible ureteroscopy and laser lithotripsy for lower pole renal calculi. Journal of Clinical Urology, 2014, 7, 389-393.	0.1	1
97	Mixed urinary incontinence- what should we treat first?. Journal of Clinical Urology, 2017, 10, 492-499.	0.1	1
98	Female stress urinary incontinence MDT. Journal of Clinical Urology, 2019, 12, 255-265.	0.1	1
99	Caseâ€finding tools for the diagnosis of OAB in women: A narrative review. Neurourology and Urodynamics, 2020, 39, 13-24.	1.5	1
100	Phenotypes of BPS/IC. Current Bladder Dysfunction Reports, 2020, 15, 203-213.	0.5	1
101	ATP shows more potential as a urinary biomarker than acetylcholine and PGE 2 , but its concentration in urine is not a simple function of dilution. Neurourology and Urodynamics, 2021, 40, 753-762.	1.5	1
102	Time for a botulinum toxin passport?. Neurourology and Urodynamics, 2020, 39, 2546-2549.	1.5	1
103	Contralateral Recurrence of Testicular Tumor: Which Patients Need Biopsy at Initial Presentation?. Current Urology, 2008, 2, 51-53.	0.6	0
104	Re: Eisenberg et al.: Endoscopic Management of Retained Foreign Bodies Following Flexible Ureterorenoscopy for Renal Calculi (Urology 2009;73:1189-1194). Urology, 2009, 74, 1380-1381.	1.0	0
105	Periurethral Injections of Non-Animal Stabilised Hyaluronic Acid/Dextranomer Gel and Sterile Abscess Formation. British Journal of Medical and Surgical Urology, 2009, 2, 174-175.	0.2	0
106	Corrigendum to "Periurethral Injections of Non-Animal Stabilised Hyaluronic Acid/Dextranomer Gel and Sterile Abscess Formation" [Brit. J. Med. Surg. Urol. 2 (4) (2009) 174â€175]. British Journal of Medical and Surgical Urology, 2009, 2, 264-264.	0.2	0
107	Parallel Incisions Procedure for Penile Curvatureâ€Short Term Outcomes. British Journal of Medical and Surgical Urology, 2011, 4, 64-67.	0.2	0
108	Overactive bladder in men: treatment options. Trends in Urology & Men's Health, 2012, 3, 13-16.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Botulinum toxinâ€A for overactive bladder: formulations, dosing and clean intermittent catheterisation. BJU International, 2013, 112, 9-10.	2.5	0
110	Urethral atrophy is fiction! Time to focus on the capsule?. BJU International, 2016, 117, 549-550.	2.5	0
111	The Artificial Urinary Sphincter. , 2016, , 145-160.		0
112	The dilemma with comparing efficacy of OAB treatments. Nature Reviews Urology, 2017, 14, 393-394.	3.8	0
113	Re: Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder. Journal of Urology, 2018, 199, 856-858.	0.4	0
114	The MIC-KEY button vesicostomy: a superior alternative for suprapubic drainage?. BJU International, 2020, 125, 299-303.	2.5	0
115	Prevalence of chronic pain following suburethral mesh sling implantation for postâ€prostatectomy incontinence. Neurourology and Urodynamics, 2021, 40, 1048-1055.	1.5	0
116	Botulinum Toxin: An Effective Treatment for Urge Incontinence. , 2009, , 257-274.		0
117	Obstructive jaundice as a presenting symptom of metastatic carcinoma of the prostate. BMJ Case Reports, 2009, 2009, bcr0520091839-bcr0520091839.	0.5	0
118	Vesicoureteric reflux diagnosed by urethral catheterisation. BMJ Case Reports, 2009, 2009, bcr0520091842-bcr0520091842.	0.5	0
119	Renal Stone on USS/X-Ray. , 2013, , 167-173.		0
120	Intravesical Therapy for Refractory Overactive Bladder and Detrusor Overactivity in Adults: Botulinum Toxin-A. Current Clinical Urology, 2014, , 135-154.	0.0	0
121	Bilateral ureteric obstruction during in vitro fertilisation therapy in a patient with complex surgically managed Crohn's disease. BMJ Case Reports, 2016, 2016, bcr2016216956.	0.5	0
122	Botulinum Toxin: An Effective Treatment for Urge Incontinence. , 2009, , 257-274.		0